Literature DB >> 26272363

MAGED1 is a negative regulator of bone remodeling in mice.

Mei Liu1, Lijuan Xu1, Xiao Ma1, Jiake Xu2, Jing Wang1, Mengmeng Xian1, Xiaotian Zhou1, Min Wang1, Fang Wang3, An Qin4, Qiuhui Pan5, Chuanjun Wen6.   

Abstract

Melanoma antigen family D1 (MAGED1), an important adaptor protein, has been shown to ubiquitously express and play critical roles in many aspects of cellular events and physiological functions. However, its role in bone remodeling remains unknown. We, therefore, analyzed the bone phenotype of Maged1-deficient mice. Maged1-deficient mice displayed a significant osteoporotic phenotype with a marked decrease in bone density and deterioration of trabecular architecture. Histomorphometric analysis demonstrated an increased mineral apposition rate as well as increased osteoclast number and surface in Maged1 knockout mice. At the cellular level, Maged1-deficient osteoblasts exhibited an increased proliferation rate and accelerated differentiation. MAGED1 deficiency also caused a promotion in osteoclastogenesis, and that was attributed to the cell autonomous acceleration of differentiation in osteoclasts and an increased receptor activator of NF-κB ligand/osteoprotegerin ratio, a major index of osteoclastogenesis, in osteoblasts. Thus, we identified MAGED1 as a novel regulator of osteoblastogenesis, osteoclastogenesis, and bone remodeling in a mouse model.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26272363     DOI: 10.1016/j.ajpath.2015.06.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  6 in total

1.  p75 neurotrophin receptor regulates differential mineralization of rat ectomesenchymal stem cells.

Authors:  Kun Yang; Yingying Wang; Yingxin Ju; Gang Li; Chang Liu; Junyu Liu; Qi Liu; Xiujie Wen; Lu Chuan Liu
Journal:  Cell Prolif       Date:  2016-09-27       Impact factor: 6.831

2.  Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats.

Authors:  Scott Taylor; Rong Hu; Efrain Pacheco; Kathrin Locher; Ian Pyrah; Michael S Ominsky; Rogely Waite Boyce
Journal:  Bone Rep       Date:  2018-03-15

3.  Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis.

Authors:  Hui Li; Jing Wang; Qiwen Sun; Gang Chen; Shengnan Sun; Xuemei Ma; Haiwen Qiu; Xuerong Liu; Liangyi Xu; Mei Liu
Journal:  Int J Mol Sci       Date:  2018-11-21       Impact factor: 5.923

4.  Phillyrin Attenuates Osteoclast Formation and Function and Prevents LPS-Induced Osteolysis in Mice.

Authors:  Jing Wang; Gang Chen; Qianqian Zhang; Fuli Zhao; Xiaolu Yu; Xuemei Ma; Mei Liu
Journal:  Front Pharmacol       Date:  2019-10-17       Impact factor: 5.810

5.  Piperlongumine Inhibits Titanium Particles-Induced Osteolysis, Osteoclast Formation, and RANKL-Induced Signaling Pathways.

Authors:  Xuan Liu; Li Diao; Yudie Zhang; Xue Yang; Junnan Zhou; Yuhang Mao; Xiaotian Shi; Fuli Zhao; Mei Liu
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

6.  VELCRO-IP RNA-seq reveals ribosome expansion segment function in translation genome-wide.

Authors:  Kathrin Leppek; Gun Woo Byeon; Kotaro Fujii; Maria Barna
Journal:  Cell Rep       Date:  2021-01-19       Impact factor: 9.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.